Business Context and Reporting Period
Company: CURIS, INC. (CRIS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: Curis is a biotechnology company focused on developing emavusertib (CA-4948), an inhibitor of IRAK4 and FLT3, primarily for hematologic malignancies. The company operates under an exclusive collaboration with Aurigene Discovery Technologies Limited. As of the filing date, the company is not in compliance with Nasdaq listing requirements regarding minimum bid price and faces substantial doubt regarding its ability to continue as a going concern.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenues, Net | $0 | $2.4 million |
| Net Loss | $(24.2) million | $(10.6) million |
| Net Loss Per Share (Basic & Diluted) | $(1.25) | $(1.25) |
| Operating Expenses | $11.5 million | $12.5 million |
| Cash and Cash Equivalents (End of Period) | $15.0 million | $20.3 million |
| Net Cash Used in Operating Activities | $(9.0) million | $(7.3) million |
| Net Cash Provided by Financing Activities | $18.9 million | $7.5 million |
| Accumulated Deficit | $(1.27) billion | $(1.25) billion |
Note: The filing text does not provide explicit gross margin or operating margin percentages due to zero revenue in the current period.
Material Changes vs. Prior Period
- Revenue Cessation: Net revenue dropped to $0 from $2.4 million in Q1 2025. This is due to the November 2025 sale of Erivedge royalty rights to TPC Investments Royalty LLC, ending the company's entitlement to royalties from Genentech/Roche.
- Increased Net Loss: Net loss widened by 128% to $24.2 million. The primary driver was a $12.8 million non-cash expense related to the change in fair value of warrant liabilities from the January 2026 PIPE Financing.
- Financing Activity: The company raised approximately $18.6 million in net proceeds through a January 2026 PIPE Financing involving convertible preferred stock and warrants. This contrasts with $8.8 million raised in March 2025.
- Expense Reduction: Research and Development (R&D) expenses decreased by 24% ($2.1 million) due to lower employee-related and manufacturing costs. General and Administrative (G&A) expenses increased by 27% ($1.1 million), largely driven by costs associated with the January 2026 financing.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
Management does not expect to generate significant revenue or achieve profitability in the foreseeable future. The company expects to continue incurring substantial losses. Current cash resources ($15.0 million) are not expected to fund operations beyond 12 months from the filing date.
Unusual Items
- Warrant Liability Reclassification: Following shareholder approval in March 2026, Series A and Series C warrants from the January 2026 PIPE were reclassified from liabilities to equity. This triggered a $14.5 million loss on the change in fair value prior to reclassification, while Series B warrants remain classified as liabilities due to an exercise price reset feature.
- Going Concern Warning: The company has concluded that conditions raise substantial doubt about its ability to continue as a going concern within one year of the report date.
Risks and Contingencies
- Nasdaq Delisting: The company received a Delist Determination Letter on April 27, 2026, for failing to maintain the $1.00 minimum bid price. Trading is scheduled to be suspended on May 6, 2026, unless a hearing panel grants additional time. The company has requested a hearing.
- Capital Needs: Substantial additional capital is required immediately to fund clinical trials for emavusertib (specifically the TakeAim CLL and TakeAim Lymphoma studies). Failure to raise capital could force the company to delay, reduce, or eliminate development programs or seek bankruptcy protection.
- Clinical Dependence: Success is heavily dependent on the clinical performance of emavusertib, which is still in early clinical development.
Investor Verification Checklist
- Capital Runway: Verify the company's ability to raise additional capital immediately, given the explicit statement that current cash will not last 12 months.
- Nasdaq Status: Monitor the outcome of the hearing regarding the delisting determination and the company's ability to regain compliance with the $1.00 minimum bid price rule.
- Warrant Liability: Review the valuation assumptions for the remaining Series B warrant liability, which remains on the balance sheet and could impact future earnings if the stock price fluctuates.
- Clinical Milestones: Track the progress of the TakeAim CLL study, specifically the dosing of the fifth patient, which is a termination trigger for the Series B warrants and a key development milestone.
- Revenue Pipeline: Confirm the status of any potential new collaborations or licensing deals, as the primary historical revenue stream (Erivedge royalties) has been sold.